# EDGAR Filing Document

**Accession Number:** 0001888012
**File Stem:** 0001193125-25-172157
**Filing Date:** 2025-8
**Character Count:** 3011
**Document Hash:** f8b236a2a450b3e833c973816ca2848d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-172157.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001193125-25-172157

**CONFORMED SUBMISSION TYPE**: SC14D9C

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HilleVax, Inc.
- **CENTRAL INDEX KEY:** 0001888012
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93640
- **FILM NUMBER:** 251177997

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** (617) 213-5054

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HilleVax, Inc.
- **CENTRAL INDEX KEY:** 0001888012
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** (617) 213-5054

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14D-9** 

**SOLICITATION/RECOMMENDATION STATEMENT** 

**PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934** 

## HILLEVAX, Inc.
**(Name of Subject Company)** 

**(Name of Person(s) Filing Statement)** 

**Common Stock, $0.0001 par value per share** 

**(Title of Class of Securities)** 

**43157M 102** 

**(CUSIP Number of Common Stock)** 

**Robert Hershberg, M.D., Ph.D.** 

**Chairman, President and Chief Executive Officer** 

**HilleVax, Inc.** 

**321 Harrison Avenue** 

**Boston, Massachusetts 02145** 

**(617) 213-5054** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications** 

**on Behalf of the Person(s) Filing Statement)** 

***With a copy to:***

**Matt T. Bush** 

**Daniel E. Rees** 

**Cheston J. Larson** 

**Latham & Watkins LLP** 

**650 Town Center Drive, 20<sup>th</sup> Floor** 

**Costa Mesa, California 92626** 

**(714) 540-1235** 

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

------

The information set forth under Items 1.01, 1.02, and 9.01 of the Current Report on Form 8-K filed by HilleVax, Inc. on August 4, 2025 (including all exhibits attached thereto) is incorporated herein by reference.